Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling
- 20 January 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (6), 1552-1566
- https://doi.org/10.1158/0008-5472.can-20-2336
Abstract
Basal and luminal subtypes of invasive bladder tumors have significant prognostic and predictive impacts for patients. However, it remains unclear whether tumor subtype commitment occurs in non-invasive urothelial lesions or in carcinoma in situ (CIS) and which gene pathways are important for bladder tumor progression. To understand the timing of this commitment, we used gene expression and protein analysis to create a global overview of 36 separate tissues excised from a whole bladder encompassing urothelium, non-invasive urothelial lesions, CIS, and invasive carcinomas. Additionally investigated were matched CIS, non-invasive urothelial lesions, and muscle-invasive bladder cancers (MIBC) from 22 patients. The final stage of subtype commitment to either a luminal or basal MIBC occurred at the CIS transition. For all tissues combined, hierarchical clustering of subtype gene expression revealed three subtypes: "luminal," "basal," and a "luminal p53-/ extracellular matrix (ECM)-like" phenotype of ECM-related genes enriched in tumor-associated urothelium, non-invasive urothelial lesions, and CIS, but rarely invasive carcinomas. A separate cohort of normal urothelium from non-cancer patients showed significantly lower expression of ECM-related genes compared to tumor-associated urothelium, non-invasive urothelial lesions, and CIS. A PanCancer Progression Panel of 681 genes unveiled pathways specific for the luminal p53-/ECM-like cluster, e.g., ECM remodeling, angiogenesis, epithelial to mesenchymal transition (EMT), cellular discohesion, cell motility involved in tumor progression; and cell proliferation and oncogenic ERBB2/ERBB3 signaling for invasive carcinomas. In conclusion, this study provides insights into bladder cancer subtype commitment and associated signaling pathways which could help predict therapy response and enhance our understanding of therapy resistance.Other Versions
Funding Information
- Friedrich-Alexander-Universität Erlangen-Nürnberg
- German Cancer Aid (70112604)
- ELAN program (P060)
This publication has 63 references indexed in Scilit:
- Comprehensive identification of mutational cancer driver genes across 12 tumor typesScientific Reports, 2013
- VAAST 2.0: Improved Variant Classification and Disease‐Gene Identification Using a Conservation‐Controlled Amino Acid Substitution MatrixGenetic Epidemiology, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- MYC on the Path to CancerCell, 2012
- Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1Molecular Cancer, 2012
- Molecular and Immunohistologic Analyses Cannot Reliably Solve Diagnostic Variation of Flat Intraepithelial Lesions of the Urinary BladderAmerican Journal of Clinical Pathology, 2010
- Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progressionUrologic Oncology, 2010
- Inactivation of p53 and Pten promotes invasive bladder cancerGenes & Development, 2009
- The Ectodomain Shedding of E-cadherin by ADAM15 Supports ErbB Receptor ActivationOnline Journal of Public Health Informatics, 2008
- ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer DiseaseNeoplasia, 2006